Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
Reuters NewMedia - December 9, 2008
The Chicago-based company is seeking Food and Drug Administration approval to sell its new version, called the FC2 Female Condom, to prevent pregnancy and HIV.
The company said it did not conduct clinical trials to show how well it prevents such outcomes because FC2 uses a new material but works the same way as the original version already on the U.S. market, the FDA staff said. Instead, the company compared the new version with the older one.
Female Health Co "asserts that such studies are not necessary. This is an important review issue," the staff wrote.
Company representatives could not be immediately reached for comment.
On Thursday, the FDA will seek advice from a panel of outside experts on whether there are enough data to show the condom is safe and effective to warrant U.S. sales.
Studies were conducted on how well the new material, a synthetic rubber called nitrile, holds up against tears and other issues, the agency said. The original condom uses polyurethane.
Both versions are comprised of a sheath with a closed ring on one end that is inserted near the cervix and an open ring on the outer end that stays outside the woman's body.
Just 10 percent of the female condom's 34.7 million unit sales in 2008 were in the United States, according to Female Health Co.
Most other countries have already adopted the newer version, which is manufactured similarly to male condoms. That process is less-costly than the current system and should reduce costs, the company has said.
U.S. consumers currently pay between 50 cents and $2 per male condom while the female version can cost nearly $4 each, according to major retail prices online.
Shares of Female Health Co. were up 2.5 percent, or 7 cents, at $2.92 in morning trade on the American Stock Exchange.
(Reporting by Susan Heavey, editing by Gerald E. McCormick and Derek Caney)
081209
RE081213
Copyright © 2008 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .